Youth Overdose & Use Reduction in Rural Systems (YOURS)
YOURS Study: Youth Overdose & Use Reduction in Rural Systems
The goal of this study is to conduct a clinical trial to understand effects of providing multilevel intervention to young people in the legal system. The multilevel intervention includes flexible care management using ACRA/ACC principles, family support, and overdose education. This study aims to test the implementation strategy, as well as the outcomes of the intervention with participants.
The first question the study will address is how successful was implementation. This will be measured by the number of youth receiving case management, family support, naloxone supplies, and overdose prevention curricula, and adoption by the participating county court systems.
The second question the study will address is whether the intervention impacted youth behavioral outcomes, such as overdose risk awareness, knowledge of how to use naloxone, and number of days per month using substances.
Researchers will compare youth who received the intervention to youth who received usual treatment to see if the intervention increases overdose risk awareness and knowledge, and decreases frequency of substance use.
Participants will receive the intervention (if assigned to) and complete study surveys. Participating counties will provide data on implementation, and site visits will also be performed to track each county's performance.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Descrizione dettagliata
Youth involved in the legal system (YILS) have some of the highest rates of substance and opioid use disorders (SUD/OUD) nationally; but few have access to adequate resources to prevent serious sequelae. SUD prevention and overdose prevention interventions for YILS are critically important to delay escalation to synthetic opioids and prevent fatalities and other health, and legal consequences.
Washington State is facing an overdose crisis; between August 2022 and 2023, overdose deaths in this state increased by 40%, a steeper increase than any other state. Rural counties in this state report overdose rates that are as high or higher than urban ones. YILS, even those without OUD, are especially vulnerable to unintentional overdose; amongst YILS incarcerated in Washington State system completing a drug and alcohol assessment, 58% had experienced an overdose at some point in the past (unpublished data). Substance use resources in this and other states for rural YILS are critical and sparse.
Working with counties on a prevention strategy will further the goal of intervening with YILS who are, on average, earlier in the spectrum of legal and substance use involvement. Prior to this trial, the research team completed a codesign process with various stakeholders to design an intervention. Codesign invites people with lived experience to the design process with the goal of designing a more effective intervention. The codesign group consisted of youth and caregivers with lived experience with substance use or the juvenile court system, behavioral health providers, funding sector representatives, and juvenile county court administrators.Participating counties will be randomized into 6 clusters of the stepped wedge design. Control group participant data collection will begin for all counties at the same time. Clusters of counties will step into the implementation stage every 3-months. When counties move into the implementation stage, intervention group participant data collection will immediately begin.
Tipo di studio
Tipo di studio
Iscrizione (Stimato)
Iscrizione
Fase
Fase
- Non applicabile
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Youth age 14-18
- Current juvenile court-involvement or receiving services from a participating county court (includes detention, diversion, truancy, at-risk youth, etc.)
- Received a REDCap link or QR code and study participation code from authorized county staff
Exclusion Criteria:
- Youth age 13 and under
- Youth who do not receive a study participation code from an authorized county contact
- Unable to participate due to significant mental health or developmental issue precluding meaningful participation in study procedures and/or intervention
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Ricerca sui servizi sanitari
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione incrociata
- Mascheramento: Doppio
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Sperimentale: Intervention: YOURS Navigator Program
The intervention consists of a navigator stationed in each participating county or shared by neighboring counties. The navigator will deliver a flexible care management intervention, including direct services and referrals to court-involved youth in rural Washington counties. |
Care Navigator who will work with youth and families to address mental health, substance use, and other unmet needs, both through direct support services as well as referrals to adjunctive agencies. The flexible care management intervention may include goal setting, skill building, contingency management, motivational interviewing, overdose prevention and education, mental health and substance first aid, and basic needs support. The Navigator will work closely with the youth for 3-months, and as-needed up to 6-months.
Altri nomi:
|
|
Nessun intervento: Usual Care
No Navigator intervention during the control time period. The juvenile court system may refer adolescents to their usual care pathways. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Overdose Prevention Knowledge
Lasso di tempo: 3- and 6-months
|
Youth knowledge on how to prevent and/or respond to an overdose. Assessed using the Opioid Overdose Knowledge Scale (OOKS). Scores range from 0-45 and a higher score is considered a better outcome. |
3- and 6-months
|
|
Presence of use past 30 days (Yes/No)
Lasso di tempo: 3- and 6-months
|
Use of any overdose associated substance (opioids, benzodiazepines, alcohol, or stimulants) in the past 30 days; use of any substance in the past 30 days |
3- and 6-months
|
|
Number of days using alcohol and cannabis
Lasso di tempo: 3- and 6-months
|
In the past 30 days, number of days youth used cannabis; in the past 30 days, number of days youth used alcohol. |
3- and 6-months
|
|
Number of youth receiving case management, mental health, or substance use prevention services
Lasso di tempo: Through study completion, up to 30 months
|
Primary implementation outcome - county level |
Through study completion, up to 30 months
|
|
Number of naloxone kits distributed
Lasso di tempo: Through study completion, up to 30 months
|
Primary implementation outcome - county level |
Through study completion, up to 30 months
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Number of days of using other individual non-alcohol/non-cannabis substances
Lasso di tempo: 3- and 6- months
|
Measure taken from the HEAL Prevention Cooperative Common Core Measures |
3- and 6- months
|
|
Substance use refusal self-efficacy
Lasso di tempo: 3- and 6-months
|
How confident youth are resisting substances. |
3- and 6-months
|
|
Percent of youth reporting receipt of naloxone
Lasso di tempo: 3 months
|
Percent of youth receiving naloxone, a medication to reverse an opioid overdose. |
3 months
|
|
Number of youth receiving overdose prevention education
Lasso di tempo: Through study completion, up to 30 months
|
Secondary implementation outcome - county level |
Through study completion, up to 30 months
|
|
Number of court staff receiving overdose prevention education
Lasso di tempo: Through study completion, up to 30 months
|
Secondary implementation outcome - county level |
Through study completion, up to 30 months
|
Altre misure di risultato
Altre misure di risultato
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Presence of non-fatal overdose
Lasso di tempo: 3- and 6-months
|
Exploratory outcome, investigator-developed |
3- and 6-months
|
Collaboratori e investigatori
Sponsor
Sponsor
Collaboratori
Collaboratori
Studiare le date dei record
Studia le date principali
Inizio studio (Stimato)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- 2026-007-SCH
- R61DA061846 (Sovvenzione/contratto NIH degli Stati Uniti)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
De-identified data will be shared with investigators who propose a specific data analysis plan that is reviewed and approved by study PIs, unless prohibited by NIDA, IRB, or another regulatory body (e.g., DSMB).
Periodo di condivisione IPD
IPD and supporting information will be available at the end of the study (March 2029) for up to 5 years (through February 2034).
Criteri di accesso alla condivisione IPD
Investigators need to submit a brief description of how they will use the data to our team to access data and supporting information. Investigators will send a dataset once the project is approved.
Tipo di informazioni di supporto alla condivisione IPD
- STUDIO_PROTOCOLLO
- LINFA
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .